German construction sector still in recession, civil engineering only bright spot
Nuvalent, Inc. (NASDAQ:NUVL), a $5.9 billion market cap biotech company, saw its Chief Financial Officer Alexandra Balcom sell a total of 27,588 shares of Class A Common Stock on September 29 and 30, 2025, for approximately $2.3 million. The sales were executed at weighted average prices ranging from $85.01 to $85.06. According to InvestingPro data, the stock is currently trading near its 52-week high of $106.32, with analysts setting price targets between $100 and $140.
According to a Form 4 filing with the Securities and Exchange Commission, the transactions occurred on September 29 and 30. On both days, Balcom also exercised options to acquire a total of 27,588 shares of Class A Common Stock at a price of $6.89, for a total value of $190,081.
Following these transactions, Balcom directly owns 61,734 shares of Nuvalent , Inc.
In other recent news, Nuvalent, Inc. has completed its New Drug Application submission to the U.S. Food and Drug Administration for zidesamtinib, targeting patients with advanced ROS1-positive non-small cell lung cancer who have been pre-treated with tyrosine kinase inhibitors. The company, based in Cambridge, Massachusetts, announced this development in a filing with the Securities and Exchange Commission. Additionally, Nuvalent plans to present pivotal data for its ROS1-selective inhibitor at the IASLC 2025 World Conference on Lung Cancer in Barcelona. This presentation will include results from the global ARROS-1 Phase 1/2 clinical trial.
In terms of analyst activity, Guggenheim has initiated coverage on Nuvalent with a Buy rating, citing the company’s potential in the lung cancer treatment market. Guggenheim believes that Nuvalent could generate significant drug sales in the future. Similarly, Piper Sandler has initiated coverage on Nuvalent with an Overweight rating, expressing optimism about the company’s potential for near-term value creation. These developments reflect growing interest in Nuvalent’s progress in the field of precision oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.